Study S002046

Individualized Pharmacological Approach to Obesity Management: A Randomized Clinical Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT03374956
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: COMPLETED
Enrollment: 193
Start: 2017-12-11
Primary completion: 2022-05-26
Lead sponsor: Mayo Clinic
Conditions: Obesity
Interventions: DRUG:Phentermine-Topiramate; DRUG:Liraglutide; DRUG:Naltrexone/bupropion; DRUG:Phentermine
Results posted: TRUE
Individual participant data sharing: NO

Registered primary outcomes

Change in Total Body Weight [baseline to 12 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027026	Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. Acosta A, Obesity (Silver Spring, Md.)	2021	Randomized trial	PMID 33759389 DOI	cites ClinicalTrials.gov:NCT03374956; registry reference DERIVED:33759389